Recent Updates
Recently added Catalysts
CORT Positive Sentiment

Corcept Announces Planned Leadership Transition

Wednesday, September 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Corcept Therapeutics has announced the retirement of Sean Maduck, the President of its Endocrinology division. Justin Gunn will take over his responsibilities starting in October. This leadership change is part of the company's ongoing strategy to enhance its focus on developing treatments for various severe disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Leadership transition indicates strategic planning.
  • Justin Gunn's appointment may bring fresh perspectives.
  • Continued focus on developing medications for serious disorders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
3.6%
average across 6 past catalysts
Lead asset
Relacorilant
Phase 2 · Adenocarcinoma

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company’s Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting October

Frequently Asked Questions

Who is retiring from Corcept Therapeutics?

Sean Maduck, the President of the Endocrinology division, is retiring.

Who will succeed Sean Maduck?

Justin Gunn will succeed Sean Maduck as President of the Endocrinology division.

When will Justin Gunn assume his new role?

Justin Gunn will fully assume his responsibilities starting in October.

What is Corcept Therapeutics focused on?

Corcept Therapeutics develops medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders.

ShareAdd on Google
Tags: CORT Viatris Investor Conferences Healthcare Corcept Therapeutics leadership change Sean Maduck Justin Gunn
Last updated: Sep 23, 2026

Biotech snapshot

Cash runway
$545M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RelacorilantPhase 2
Adenocarcinoma →

Catalyst track record

+283%
best trade around CORT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CORT.

See every catalyst's timing & PoA →